4D Molecular Therapeutics (FDMT) Net Equity Issued and Repurchased (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $9.7 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $9.7 million in Q1 2026; TTM through Mar 2026 was $9.7 million, a 149.4% increase from a year earlier, with the FY2025 full-year figure at $9.6 million, down 37.1% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $9.7 million, up from -$19.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for FDMT reached as high as $315.7 million in Q1 2024 and fell as low as -$19.6 million in Q2 2024.
• Historically, Net Equity Issued and Repurchased has averaged $54.2 million across 3 years, with a median of $9.6 million in 2023.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 3172.72% in 2024 and fell as far as 3172.72% in 2024.
• Year by year, Net Equity Issued and Repurchased stood at $1000.0 in 2023, then plunged by 1963800.0% to -$19.6 million in 2024, then jumped by 149.4% to $9.7 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $9.7 million in Q1 2026, -$19.6 million in Q2 2024, and $315.7 million in Q1 2024.